A report of three patients with an interstitial deletion of chromosome 15q24
Version of Record online: 8 JUL 2005
Copyright © 2005 Wiley-Liss, Inc.
American Journal of Medical Genetics Part A
Volume 137A, Issue 1, pages 65–71, 15 August 2005
How to Cite
Cushman, L. J., Torres-Martinez, W., Cherry, A. M., Manning, M. A., Abdul-Rahman, O., Anderson, C. E., Punnett, H. H., Thurston, V. C., Sweeney, D. and Vance, G. H. (2005), A report of three patients with an interstitial deletion of chromosome 15q24. Am. J. Med. Genet., 137A: 65–71. doi: 10.1002/ajmg.a.30836
- Issue online: 20 JUL 2005
- Version of Record online: 8 JUL 2005
- Manuscript Accepted: 2 MAY 2005
- Manuscript Received: 12 AUG 2004
- chromosome 15;
- deletion (15)(q24);
- partial monosomy 15q
Partial monosomy of the q2 region of chromosome 15 has been infrequently reported. Moreover, interstitial deletions involving 15q22-q24 have been described in only nine patients to date. The phenotype of these reported individuals is subject to the extent of the deletion but typically includes altered muscle tone and significant developmental delays. In addition, eye abnormalities, such as strabismus, microphthalmia, or colobomas, ear abnormalities including cleft earlobe and preauricular tags, and urogenital defects are common features. Congenital heart defects, diaphragmatic hernia, abnormalities of the central nervous system, and skeletal anomalies have been reported but appear to be less frequent clinical manifestations. In this report, we describe three new patients with interstitial deletions involving 15q24, two with cryptic deletions identified by fluorescence in situ hybridization (FISH) with a probe for the PML gene and one with a cytogenetically visible deletion of 15q22.3-q24. The clinical presentation of these individuals is similar to those previously described and includes global developmental delays, hypotonia, and genital abnormalities in the males. The identification of these three cases demonstrates that the above clinical features are associated with a new cytogenetic deletion syndrome. Furthermore, we suggest that FISH analysis with a probe for the PML gene be performed in patients with these physical findings. © 2005 Wiley-Liss, Inc.